Many different microbes can cause pneumonia, and treatment may be delayed or off target if doctors cannot tell which bug is the culprit. A novel approach, analyzing a patient's breath for key chemical compounds made by the infecting microbe, may help detect invasive aspergillosis, a fungal infection that is a leading cause of mortality in patients with compromised immune systems, according to a proof-of-concept study now online in Clinical Infectious Diseases.
Currently difficult to diagnose, this type of fungal pneumonia often requires a lung biopsy for definitive identification. For debilitated patients with weakened immune systems, including organ or bone marrow transplant recipients and patients on chemotherapy, such an invasive procedure may be challenging. A non-invasive method that can also identify the type of fungus causing pneumonia could lead to earlier and more targeted treatment in these cases. Researchers wondered if they could find a unique "chemical signature" in the breath of patients being evaluated for fungal pneumonia. In the lab, they identified several compounds, or metabolites, normally produced by Aspergillus fumigatus and other fungi that can cause pneumonia.
The researchers then analyzed breath samples from 64 patients with suspected cases of invasive aspergillosis and assessed whether it was possible to distinguish patients with this fungal pneumonia from patients who did not have this illness. Based on the identification of these fungal compounds in the breath samples, they identified patients with the fungal infection with high accuracy—94 percent sensitivity and 93 percent specificity. (In other words, the method was able to detect 94 percent of patients who actually had or likely had the disease, and misidentified as infected 7 percent of patients who were not actually infected.)
There were no adverse events related to the breath collection procedure, the authors reported. It was well-tolerated, including by patients who had difficulty breathing or required supplemental oxygen. More research will be needed to validate the findings and refine the approach before it can be considered for clinical use, the authors noted. If supported by future research, the method also may have applications in other kinds of pneumonia.